Trinity Biotech Soars 39.42% on HIV Test Manufacturing Approval

Trinity Biotech's stock surged by 39.42% in pre-market trading on August 20, 2025, marking a significant rise that has caught the attention of investors and analysts alike.

Trinity Biotech has received regulatory approval to commence offshore and outsourced manufacturing of its flagship rapid HIV test, the TrinScreen HIV test. This approval is a pivotal moment for the company, allowing it to transition its production from in-house operations to a more cost-effective and scalable outsourced model. The shift is expected to enhance gross margins and support the company's strategic transformation.

The approval enables Trinity Biotech to launch this service through its New York reference laboratory in the third quarter of 2025. This move is part of the company's broader strategy to optimize its operations and improve its financial performance. The TrinScreen HIV test, prequalified by the World Health Organization, is a critical product for Trinity Biotech, and this approval is a significant milestone in its journey to expand its market reach and operational efficiency.